G. HASBAL ÇELİKOK Et Al. , "Identification of AKT1/beta-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment," ONCOLOGY LETTERS , vol.21, no.3, 2021
HASBAL ÇELİKOK, G. Et Al. 2021. Identification of AKT1/beta-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment. ONCOLOGY LETTERS , vol.21, no.3 .
HASBAL ÇELİKOK, G., Aksoy-Sagirli, P., Altiparmak-Ulbegi, G., & Can, A., (2021). Identification of AKT1/beta-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment. ONCOLOGY LETTERS , vol.21, no.3.
HASBAL ÇELİKOK, Gözde Et Al. "Identification of AKT1/beta-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment," ONCOLOGY LETTERS , vol.21, no.3, 2021
HASBAL ÇELİKOK, Gözde H. Et Al. "Identification of AKT1/beta-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment." ONCOLOGY LETTERS , vol.21, no.3, 2021
HASBAL ÇELİKOK, G. Et Al. (2021) . "Identification of AKT1/beta-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment." ONCOLOGY LETTERS , vol.21, no.3.
@article{article, author={Gözde HASBAL ÇELİKOK Et Al. }, title={Identification of AKT1/beta-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment}, journal={ONCOLOGY LETTERS}, year=2021}